作者
Eric Segal, Michael Martens, Hai‐Lin Wang, Ruta Brazauskas, Daniel Weisdorf, Brenda M Sandmaier, H Jean Khoury, Marcos de Lima, Wael Saber
发表日期
2017/9/1
期刊
Cancer
卷号
123
期号
17
页码范围
3346-3355
简介
BACKGROUND
Allogeneic hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)–matched related donors (RDs) and allogeneic HCT using HLA‐matched unrelated donors (URDs) produce similar outcomes for patients with acute myelogenous leukemia, whereas the donor source has been reported to be a predictor of outcomes in myelodysplastic syndrome.
METHODS
Post‐HCT outcomes for 1458 acute lymphoblastic leukemia patients from 2000 to 2011 were analyzed, and RD and URD transplants were compared.
RESULTS
The median age was 37 years (range, 18‐69 years). In the multivariate analysis, HLA 8/8 allele–matched URD recipients had similar transplant‐related mortality (TRM) and all‐cause mortality in comparison with RD recipients (hazard ratios [HRs], 1.16 [95% confidence interval (CI), 0.91‐1.48] and 1.01 [95% CI, 0.85‐1.19], respectively); 7/8 URD recipients had …
学术搜索中的文章
E Segal, M Martens, HL Wang, R Brazauskas… - Cancer, 2017
E Segal, M Martens, HL Wang, R Brazauskas… - Blood, 2015